Related Experiment Video

Updated: Oct 9, 2026

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method
09:32

Procedure and Key Optimization Strategies for an Automated Capillary Electrophoretic-based Immunoassay Method

Published on: September 10, 2017

Sensitivity of anticancer drugs in Saos-2 cells transfected with mutant p53 varied with mutation point

L H Wang1, K Okaichi, M Ihara

  • 1Department of Radiation Biophysics, Nagasaki University School of Medicine, Japan.

Anticancer Research
|May 6, 1998
PubMed

Insights

The p53 gene

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • The p53 tumor suppressor gene plays a critical role in cellular responses to DNA damage.
  • Osteosarcoma is a primary bone cancer where p53 status can influence treatment outcomes.
  • Understanding p53's role in drug resistance is crucial for developing effective cancer therapies.

Purpose of the Study:

  • To investigate the impact of wild-type and various mutant p53 gene transfections on the sensitivity of osteosarcoma cells to common anticancer drugs.
  • To determine if specific p53 mutations confer differential resistance or sensitivity to chemotherapy agents.

Main Methods:

  • Utilized the Saos-2 human osteosarcoma cell line, which lacks endogenous p53.
  • Transfected Saos-2 cells with wild-type p53 and specific mutant p53 genes (123A, 143A, 175H, 273H).
  • Assessed the surviving fraction of transfected cells after exposure to cisplatin (CDDP), nimustine (ACNU), adriamicin (ADR), and bleomycin (BLM).

Main Results:

  • Mutant p53 transfectants (143A, 175H, 273H) showed significantly increased resistance to cisplatin (CDDP) compared to controls.
  • Wild-type p53 and mutant 123A p53 transfectants exhibited significantly higher sensitivity to nimustine (ACNU).
  • Mutant 123A p53 transfectants were more sensitive to adriamicin (ADR), while bleomycin (BLM) sensitivity remained unchanged across all cell lines.

Conclusions:

  • The mutation point of the p53 gene significantly influences the sensitivity of osteosarcoma cells to specific anticancer drugs.
  • Different p53 mutations confer distinct resistance or sensitivity profiles to chemotherapy, highlighting the importance of p53 status in treatment response.
  • These findings suggest that p53 genotype could be a predictive biomarker for chemotherapy efficacy in osteosarcoma.

More Related Videos

Yeast As a Chassis for Developing Functional Assays to Study Human P5314:57

Yeast As a Chassis for Developing Functional Assays to Study Human P53

Published on: August 4, 2019

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence04:56

Detection of Aggregation-Prone Behavior in Mutant P53 V157F Breast Cancer Cells Using Multipoint Thioflavin T Fluorescence

Published on: December 30, 2025

Related Concept Videos

Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...